Estimation and correction of produced light from prompt gamma photons on luminescence imaging of water for proton therapy dosimetry.
Estimation and correction of produced light from prompt gamma photons on luminescence imaging of water for proton therapy dosimetry. Phys Med Biol. 2018 Jan 19;: Authors: Yabe T, Komori M, Toshito T, Yamaguchi M, Kawachi N, Yamamoto S Abstract Although the luminescence images of water during proton-beam irradiation using a cooled charge-coupled device (CCD) camera showed almost the same ranges of proton beams as those measured by an ionization chamber, the depth profiles showed lower Bragg peak intensities than those measured by an ionization chamber. In addition, a broad optical baseline signal was observed in depths that exceed the depth of Bragg peak. We hypothesize that this broad baseline signal originates from interaction of proton-induced prompt gamma photons with water. These prompt gamma photons interact with water to form high-energy Compton electrons, which may cause luminescence or Cherenkov emission from depths exceeding the location of Bragg peak. To clarify this idea, we measured the luminescence images of water during the irradiations of protons in water with minimized parallax errors, and also simulated the produced light by the interactions of prompt gamma photons with water. We corrected the measured depth profiles of the luminescence images by subtracting the simulated distributions of the produced light by the interactions of prompt gamma photons in water. Corrections were also conducted using the estimated depth profiles of the ligh...
Authors: Mailhot Vega RB, Hoppe BS PMID: 31976780 [PubMed - as supplied by publisher]
We propose linear-energy-transfer (LET)-guided robust optimization in intensity-modulated proton therapy (IMPT) for head-and-neck (H&N) cancer. This method simultaneously considers LET and physical dose distributions of tumors and organs-at-risk (OARs) with uncertainties.
To report institutional outcomes following proton therapy for pelvic rhabdomyosarcoma (RMS).
Abstract Patients with squamous cell carcinoma of the oropharynx are generally treated with (chemo) radiation. Patients with oropharyngeal cancer (OPC) have better survival than patients with squamous cell carcinoma of other head and neck subsites, especially when related to human papillomavirus (HPV). However, radiotherapy results in a substantial percentage of survivors suffering from significant treatment-related side-effects. Late radiation-induced side-effects are mostly irreversible and may even be progressive, and particularly xerostomia and dysphagia affect health-related quality of life (HRQoL). As the ri...
Hitachi Healthcare Americas plans to launch a new medical imaging innovation...Read more on AuntMinnie.comRelated Reading: Hitachi board votes to sell medical division to Fujifilm Report: Fujifilm plans to buy Hitachi imaging business Hitachi delivers proton therapy unit to Sibley Memorial Hitachi takes order for particle therapy system Hitachi features CT, MRI technology at ECR 2019
ConclusionsThe results suggest that CCPT is an effective treatment for cT1 ESCC and careful endoscopic follow-up allows preferable local control with salvage endoscopic treatment.
Conclusion: Proton dose-painting for HNC seems feasible and can reduce the non-target dose overall, however not significantly to certain organs close to the target, such as the salivary glands. Max dose in proton plans had a lower robustness compared to photons, requiring caution to avoid unintended hot spots in consideration of the risk of mucosal toxicity. PMID: 31964199 [PubMed - as supplied by publisher]
PALO ALTO, Calif., Jan. 20, 2020 -- (Healthcare Sales &Marketing Network) -- Varian (NYSE: VAR) today announced it has appointed Dr. Ricky Sharma, to vice president of Clinical Affairs. In this role he will be leading medical research, translational scie... Devices, Oncology, Personnel Varian Medical Systems, radiotherapy, proton therapy
CONCLUSION: Both systems showed a good capacity to produce satisfactory plans, with Eclipse™ being able to achieve better target coverage and plan homogeneity without compromising OARs. ADVANCES IN KNOWLEDGE: A benchmark between a clinically tested and validated system with a commercial solution is of interest for emerging proton therapy, equipped with commercial systems and no previous experience with PBS. PMID: 31944827 [PubMed - as supplied by publisher]
A new proton therapy center is making its debut on the campus of the University of Alabama at Birmingham. The new facility was developed by Proton International in partnership with UAB. It is located on 20th Street South between Fourth and Fifth avenues. UAB officials say the new center will mark another big step toward advancing cancer care in Alabama. “With the establishment of this center, UA B Medicine has again brought one of the latest, most advanced medical technologies to our region,”…